The Effect of Treatment with an LH-RH Agonist (Buserelin) on Gonadal Activity, Growth, and Bone Maturation in Children with Central Precocious Puberty
May 1987
in “
European Journal of Pediatrics
”
TLDR Buserelin safely and effectively suppresses early puberty, potentially improving final height.
The study from 1987 involved 25 children with central precocious puberty treated with the LH-RH agonist Buserelin for 11-18 months. The treatment effectively suppressed gonadal activity, as evidenced by decreased estrogen and testosterone levels, cessation of menstruation in girls, and reduced testicular volume in boys. Growth rates initially varied, with a decline observed over the subsequent year. The study concluded that Buserelin was a safe and effective method for inhibiting gonadal activity, with potential for improved final height prediction with prolonged treatment.